Business Context and Reporting Period
This Form 6-K filing by GSK plc (the "Company") reports a transaction in its own shares for the month of August 2025. The filing details a share repurchase executed on August 15, 2025, pursuant to a non-discretionary agreement with Merrill Lynch International entered into on June 4, 2025.
Key Financial Metrics and Transaction Details
The filing focuses exclusively on share buyback activity and does not provide revenue, profit, cash flow, margin, or debt metrics.
- Shares Purchased (August 15, 2025): 436,588 ordinary shares.
- Price Range: Lowest 1,414.50p; Highest 1,429.50p.
- Volume-Weighted Average Price (VWAP): 1,423.56p.
- Trading Venue: London Stock Exchange (XLON).
- Cumulative Buyback (Since June 4, 2025): 24,142,993 ordinary shares.
- Treasury Shares Held: 242,277,376 ordinary shares.
- Shares in Issue (Excluding Treasury): 4,073,114,358 ordinary shares.
- Treasury Voting Rights Percentage: 5.95%.
Material Changes
The filing reports a reduction in the number of shares in issue and an increase in treasury shares following the August 15 transaction. The total number of voting rights remains 4,073,114,358, which serves as the denominator for shareholder notification calculations under FCA Disclosure Guidance and Transparency Rules.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding operational performance. It includes a standard cautionary statement noting that forward-looking statements are subject to risks and uncertainties, referencing the "Risk Factors" section in GSK's 2024 Annual Report on Form 20-F and Q2 2025 Results.
Investor Verification Checklist
- Verify the total remaining authorization under the share buyback programme announced on June 4, 2025.
- Confirm the current market price relative to the VWAP of 1,423.56p paid on August 15.
- Review the "Risk Factors" in the 2024 Form 20-F for context on the company's broader financial health, as this filing contains no operational data.
- Monitor future 6-K filings to track the progress of the cumulative buyback towards the programme's conclusion.